Alto Neuroscience, Inc. (NYSE:ANRO)
Health Care/Life Sciences • Biotechnology
CIK 1999480
Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.
Address
369 South San Antonio Road
Los Altos, California 94022
369 South San Antonio Road
Los Altos, California 94022
Employees
None
None
Stock Info
Key Executives
Board Of Directors
|
Chairman, President & Chief Executive Officer Amit Etkin MD, PhD |
|
Director Po Yu Chen PhD |
|
Director Aaron N. D Weaver CFA |
|
Lead Independent Director Christopher Nixon Cox |
|
Independent Director Gwill E York MBA |
|
Independent Director Andrew Dreyfus |
SEC filings
| Date | Form | Event |
|---|---|---|
| 13 Aug, 2024 | 8-K | |
| 13 Aug, 2024 | 10-Q | |
| 29 Jul, 2024 | 8-K | |
| 11 Jul, 2024 | 4 | |
| 22 May, 2024 | 3 | |
| 22 May, 2024 | 4 | |
| 21 May, 2024 | 8-K | |
| 14 May, 2024 | 10-Q | |
| 14 May, 2024 | 8-K | |
| 1 Apr, 2024 | 4 | |
| 29 Mar, 2024 | SC 13G | |
| 21 Mar, 2024 | 8-K | |
| 21 Mar, 2024 | 10-K | |
| 12 Mar, 2024 | 4 | |
| 12 Mar, 2024 | 3 | |
| 11 Mar, 2024 | 8-K | |
| 6 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 9 Feb, 2024 | SC 13G | |
| 8 Feb, 2024 | 4 | |
| 7 Feb, 2024 | SC 13G | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 6 Feb, 2024 | 8-K | |
| 6 Feb, 2024 | S-8 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 424B4 | IPO completed |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 2 Feb, 2024 | SEC STAFF | |
| 2 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | S-1MEF | |
| 1 Feb, 2024 | EFFECT | |
| 1 Feb, 2024 | 3 | |
| 30 Jan, 2024 | CERT | |
| 30 Jan, 2024 | CORRESP | |
| 30 Jan, 2024 | CORRESP | |
| 30 Jan, 2024 | 8-A12B | |
| 29 Jan, 2024 | S-1/A | |
| 29 Jan, 2024 | S-1/A | |
| 25 Jan, 2024 | CORRESP | |
| 24 Jan, 2024 | CORRESP | |
| 23 Jan, 2024 | UPLOAD | |
| 19 Jan, 2024 | CORRESP | |
| 12 Jan, 2024 | CORRESP | |
| 12 Jan, 2024 | S-1 | |
| 9 Jan, 2024 | UPLOAD | |
| 9 Jan, 2024 | SEC STAFF | |
| 28 Dec, 2023 | DRSLTR | |
| 28 Dec, 2023 | DRS/A | |
| 19 Dec, 2023 | UPLOAD | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 22 Nov, 2023 | DRS |
Last update:2024-03-12 12:03:26.499748
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.